Nanoparticle Formulation of Rosuvastatin: Enhancing Solubility and Clinical Potential

Assoc. Prof., Dr. Le Quang Huan¹, Dr. Ha Thi Thanh Huong¹, Doctor. Dao Huu Hoang², Specialist level 2 Doctor. Van Tat Chien², Nguyen Minh Hien³, Ngo Phuong Thuy³ – ¹Hoa Binh University, ²SPM Joint Stock Company, ³VNU University of Medicine and Pharmacy

Abstract:

Rosuvastatin is a potent statin used in the management of dyslipidemia and the prevention of cardiovascular diseases. However, its low water solubility limits bioavailability and therapeutic outcomes. This study outlines a nanotechnology-based method to enhance its solubility and absorption of rosuvastatin. The process entails the formulation of rosuvastatin nanoparticles through a combination of precipitation and ultrasonic techniques. Rosuvastatin is initially dissolved in an organic solvent, such as acetone, and subsequently mixed with an aqueous phase containing stabilizers like Poloxamer 407 or PVP to induce precipitation. Ultrasound reduces particle size to 50-200 nm. Key parameters, including drug-to-stabilizer ratio, stirring speed, ultrasound duration, and temperature, were systematically optimized to archive uniform, nanoscale particles. The resulting nanoparticles exhibit improved stability and solubility, achieving a 6.8-fold increase compared to unmodified Rosuvastatin. Additionally, the application of nanotechnology safeguards the drug against gastric degradation, reduces the required dosage, and minimizes potential side effects. This approach offers promising applications for poorly soluble drugs and significantly improves therapeutic efficiency, marking a step forward in pharmaceutical development for better patient outcomes.

See file

Keywords: Rosuvastatin, cardiovascular, solubility, cancer, nanoparticle.